{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:24:29Z","timestamp":1759710269897,"version":"build-2065373602"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.mehy.2020.110018","type":"journal-article","created":{"date-parts":[[2020,6,20]],"date-time":"2020-06-20T20:05:58Z","timestamp":1592683558000},"page":"110018","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Is it possible to use Proton Pump Inhibitors in COVID-19 treatment and prophylaxis?"],"prefix":"10.1016","volume":"143","author":[{"given":"\u015eeyma","family":"Ta\u015ftemur","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hilmi","family":"Ataseven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.mehy.2020.110018_b0005","doi-asserted-by":"crossref","first-page":"650","DOI":"10.4161\/viru.32077","article-title":"Middle East respiratory syndrome (MERS): a new zoonotic viral pneumonia","volume":"5","author":"Cunha","year":"2014","journal-title":"Virulence"},{"issue":"14","key":"10.1016\/j.mehy.2020.110018_b0010","doi-asserted-by":"crossref","first-page":"7790","DOI":"10.1128\/JVI.01244-13","article-title":"Middle east Rrespiratory yndrome coronavirus (MERS-CoV): announcement of the Coronovirus Study Group","volume":"87","author":"De Groot","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.mehy.2020.110018_b0015","unstructured":"World Health Organization. Coronavirus disease 2019 (COVID-19) Situation Report \u2013 67. 27 March 2020. https:\/\/www.who.int\/docs\/default-source\/coronaviruse\/situation-reports\/20200327-sitrep-67-covid-19.pdf?sfvrsn=b65f68eb_4."},{"issue":"3","key":"10.1016\/j.mehy.2020.110018_b0020","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/tmi.13383","article-title":"The COVID-19 epidemic","volume":"25","author":"Velavan","year":"2020","journal-title":"Trop Med Int Health"},{"key":"10.1016\/j.mehy.2020.110018_b0025","article-title":"Immunopathological characteristics of coronavirus disease 2019 cases in Guangzhou, China","author":"Shi","year":"2020","journal-title":"Immunology"},{"key":"10.1016\/j.mehy.2020.110018_b0030","doi-asserted-by":"crossref","unstructured":"Zhang B, Zhou X, Zhu C et al. Immune phenotyping based on neutrophil-to-lymphocyte ratio and IgG predicts disease severity and outcome for patients with COVID-19. medRxiv; 2020. https:\/\/doi.org\/10.1101\/2020.03.12.20035048.","DOI":"10.1101\/2020.03.12.20035048"},{"key":"10.1016\/j.mehy.2020.110018_b0035","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.mehy.2020.110018_b0040","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41577-020-0308-3","article-title":"COVID-19: immunopathology and its implications for therapy","volume":"20","author":"Cao","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.mehy.2020.110018_b0045","first-page":"14","article-title":"Drug repositioning an alternative for the treatment of coronavirus COVID-19","volume":"11","author":"Serafin","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.mehy.2020.110018_b0050","unstructured":"Kamps BS, Hoffmann C. COV\u0130D Reference. Eng\/2020.3 Third Edition. ISBN:978-3-942687-46-1 https:\/\/amedeo.com\/CovidReference03.pdf."},{"key":"10.1016\/j.mehy.2020.110018_b0055","first-page":"32","article-title":"Targeting autophagy with small molecules for cancer therapy","volume":"5","author":"Kondapuram","year":"2019","journal-title":"J Cancer Metastasis Treat"},{"key":"10.1016\/j.mehy.2020.110018_b0060","doi-asserted-by":"crossref","unstructured":"Nabirotchkin S, Peluffo AE, Bouaziz J, Cohen D. Focusing on the Unfolded Protein Response and Autophagy Related Pathways to Reposition Common Approved Drugs against COVID-19. Prepint. 2020. https:\/\/doi.org\/10.20944\/preprints202003.0302.v1.","DOI":"10.20944\/preprints202003.0302.v1"},{"key":"10.1016\/j.mehy.2020.110018_b0065","doi-asserted-by":"crossref","unstructured":"Sinha, N, Balayla, G. (2020). Hydroxychloroquine and covid-19. Postgraduate Med J, 2002. postgradmedj\u2013137785. https:\/\/doi.org\/10.1136\/postgradmedj-2020-137785.","DOI":"10.1136\/postgradmedj-2020-137785"},{"issue":"5","key":"10.1016\/j.mehy.2020.110018_b0070","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s11427-009-0061-0","article-title":"Influenza A virus H5N1 entry into host cells is through clathrin-dependent endocytosis","volume":"52","author":"Wang","year":"2009","journal-title":"Sci China, Ser C Life Sci"},{"issue":"11","key":"10.1016\/j.mehy.2020.110018_b0075","doi-asserted-by":"crossref","first-page":"5642","DOI":"10.1128\/JVI.78.11.5642-5650.2004","article-title":"pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN","volume":"78","author":"Yang","year":"2004","journal-title":"J Virol"},{"issue":"3","key":"10.1016\/j.mehy.2020.110018_b0080","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41584-020-0372-x","article-title":"Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology","volume":"16","author":"Schrezenmeier","year":"2020","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"10.1016\/j.mehy.2020.110018_b0085","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1093\/jac\/dkv018","article-title":"Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases","volume":"70","author":"Al-Bari","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.mehy.2020.110018_b0090","doi-asserted-by":"crossref","unstructured":"Damle B, Vourvahis M, Wang E, Leaney J, Corrigan B. Clinical Pharmacology Perspectives on the Antiviral Activity of Azithromycin and Use in COVID\u201019. Clin Pharmacol Ther.2020. Accepted Author Manuscript. https:\/\/doi.org\/10.1002\/cpt.1857.","DOI":"10.1002\/cpt.1857"},{"issue":"1","key":"10.1016\/j.mehy.2020.110018_b0095","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1006\/excr.2002.5613","article-title":"Azithromycin, a lysosomotropic antibiotic, has distinct effects on fluidphase and receptor-mediated endocytosis, but does not impair phagocytosis in J774 macrophages","volume":"281","author":"Tyteca","year":"2002","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.mehy.2020.110018_b0100","doi-asserted-by":"crossref","unstructured":"Homolak J. Kodvanj I. Widely Available Lysosome Targeting Agents Should Be Considered as a Potential Therapy for COVID-19. Preprint.2020. 2020030345. https:\/\/doi.org\/10.20944\/preprints202003.0345.v2.","DOI":"10.20944\/preprints202003.0345.v2"},{"issue":"6","key":"10.1016\/j.mehy.2020.110018_b0105","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1128\/jvi.64.6.3042-3050.1990","article-title":"Conformational change of the coronavirus peplomer glycoprotein at pH 8.0 and 37 degrees C correlates with virus aggregation and virus-induced cell fusion","volume":"64","author":"Sturman","year":"1990","journal-title":"J Virol"},{"key":"10.1016\/j.mehy.2020.110018_b0110","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0065-3527(08)60583-7","article-title":"Virus entry into animal cells","volume":"36","author":"Marsh","year":"1989","journal-title":"Adv Virus Res"},{"issue":"4","key":"10.1016\/j.mehy.2020.110018_b0115","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1128\/jvi.65.4.1916-1928.1991","article-title":"Alteration of the pH dependence of coronavirus-induced cell fusion: effect of mutations in the spike glycoprotein","volume":"65","author":"Gallagher","year":"1991","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.mehy.2020.110018_b0120","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1177\/153567600701200206","article-title":"Evaluation of SARS-coronavirus decontamination procedures","volume":"12","author":"Pagat","year":"2007","journal-title":"Appl Biosaf"},{"key":"10.1016\/j.mehy.2020.110018_b0125","unstructured":"Ta\u015ftemur \u015e, Ataseven H. Proton Pompa \u0130nhibit\u00f6rleri ve Kanser. Ataseven H, Erg\u00fcl M, edit\u00f6r. Her Y\u00f6n\u00fcyle Proton Pompalar\u0131 ve Proton Pompa \u0130nhibit\u00f6rleri. 1. Bask\u0131. Sivas. P:171-182. 2020. ISBN: 978-605-7902-32-0."},{"issue":"5","key":"10.1016\/j.mehy.2020.110018_b0130","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1136\/gut.33.5.617","article-title":"Effects of omeprazole on neutrophil chemotaxis, superoxide production, degranulation, and translocation of cytochrome b\u2212245","volume":"33","author":"Wandall","year":"1992","journal-title":"Gut"},{"key":"10.1016\/j.mehy.2020.110018_b0135","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s10156-009-0728-2","article-title":"Downregulation of immunomodulator gene expression in LPS-stimulated human polymorphonuclear leukocytes by the proton pump inhibitor lansoprazol","volume":"15","author":"Ubagai","year":"2009","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.mehy.2020.110018_b0140","doi-asserted-by":"crossref","unstructured":"Bicakci U, Tander B, Ariturk E, and all. Effects of omeprazole and gentamicin on the biochemical and histopathological alterations of the hypoxia\/reoxygenation induced intestinal injury in newborn rats. Pediatr Surg Int 2005;21(10):800\u2013805. https:\/\/doi.org\/10.1007\/s00383-005-1538-y.","DOI":"10.1007\/s00383-005-1538-y"},{"issue":"3","key":"10.1016\/j.mehy.2020.110018_b0145","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.bbrc.2006.04.170","article-title":"all. Beyond gastric acid reduction: proton pump inhibitors induce heme oxygenase-1 in gastric and endothelial cells","volume":"345","author":"Becker","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"10.1016\/j.mehy.2020.110018_b0150","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1128\/AAC.43.5.1304","article-title":"Synergistic in vitro antimalarial activity of omeprazole and quinine","volume":"43","author":"Skinner-Adams","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.mehy.2020.110018_b0155","first-page":"161","article-title":"A double blind, randomised placebo controlled trial of rifampicin with omeprazole in the treatment of human cutaneous leishmaniasis","volume":"43","author":"Kochar","year":"2006","journal-title":"J Vect Borne Dis"},{"key":"10.1016\/j.mehy.2020.110018_b0160","doi-asserted-by":"crossref","unstructured":"MichaelisM,KleinschmidtMC,BojkovaD,RabenauHF,WassMN,CinatlJJr. Omeprazole increases the efficacy of acyclovir against herpes simplex virus type 1 and 2.Front Microbiol 20193;10:2790. https:\/\/doi.org\/10.3389\/fmicb.2019.02790.","DOI":"10.3389\/fmicb.2019.02790"},{"key":"10.1016\/j.mehy.2020.110018_b0165","doi-asserted-by":"crossref","unstructured":"Bojkova D,McGreig JE, McLaughlin KM et al. SARS-CoV-2 and SARS-CoV differ in their cell tropism and drug sensitivity profiles. bioRxiv; 2020. https:\/\/doi.org\/10.1101\/2020.04.03.024257.","DOI":"10.1101\/2020.04.03.024257"},{"key":"10.1016\/j.mehy.2020.110018_b0170","doi-asserted-by":"crossref","unstructured":"Zuo W, Zhao X, Chen, YG. 2009. SARS Coronavirus and Lung Fibrosis.Molecular Biology of the SARS-Coronavirus, 247\u2013258. https:\/\/doi.org\/10.1007\/978-3-642-03683-5_15.","DOI":"10.1007\/978-3-642-03683-5_15"},{"issue":"5","key":"10.1016\/j.mehy.2020.110018_b0175","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1183\/09031936.00125407","article-title":"Decreased expression of haem oxygenase-1 by alveolar macrophages in idiopathic pulmonary fibrosis","volume":"31","author":"Ye","year":"2008","journal-title":"Eur Respir J"},{"key":"10.1016\/j.mehy.2020.110018_b0180","doi-asserted-by":"crossref","unstructured":"Hammond CL, Roztocil E, Phipps RP, Feldon SE, Woeller CF. Proton pump inhibitors attenuate myofibroblast formation associated with thyroid eye disease through the aryl hydrocarbon receptor. PLoSONE 14(9):e0222779. https:\/\/doi.org\/10.1371\/journal.pone.0222779.","DOI":"10.1371\/journal.pone.0222779"},{"key":"10.1016\/j.mehy.2020.110018_b0185","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3389\/fphar.2017.00016","article-title":"Therapeutic efficacy of esomeprazole in cotton smoke-induced lung injury model","volume":"8","author":"Nelson","year":"2017","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.mehy.2020.110018_b0190","doi-asserted-by":"crossref","first-page":"499","DOI":"10.3389\/fphar.2018.00499","article-title":"Proton pump inhibitors in IPF: a call for clinical trials","volume":"9","author":"Ghebre","year":"2018","journal-title":"Front Pharmacol"},{"issue":"2","key":"10.1016\/j.mehy.2020.110018_b0195","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1177\/0961203308097574","article-title":"The potential negative impact of proton pump inhibitors on the immunopharmacologic effects of chloroquine and hydroxychloroquine","volume":"18","author":"Namazi","year":"2009","journal-title":"Lupus"},{"issue":"12","key":"10.1016\/j.mehy.2020.110018_b0200","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1517\/17425255.2012.722757","article-title":"The effects of gastric bypass surgery on drug absorption and pharmacokinetics","volume":"8","author":"Brocks","year":"2012","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.mehy.2020.110018_b0205","doi-asserted-by":"crossref","unstructured":"Thomas DE, LyonsJS, GreeneBS, Petri MA. Low hydroxychloroquine blood levels in patients who have had gastric bypass surgery. Lupus Sci Med 2019;16:6(1):e000335. https:\/\/doi.org\/10.1136\/lupus-2019-000335.","DOI":"10.1136\/lupus-2019-000335"},{"issue":"8","key":"10.1016\/j.mehy.2020.110018_b0210","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1002\/art.39194","article-title":"Determinants of hydroxychloroquine blood concentration variations in systemic lupus erythematosus","volume":"67","author":"Jallouli","year":"2015","journal-title":"Arthritis Rheumatol"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030698772031166X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030698772031166X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T19:26:31Z","timestamp":1759692391000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030698772031166X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":42,"alternative-id":["S030698772031166X"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2020.110018","relation":{},"ISSN":["0306-9877"],"issn-type":[{"type":"print","value":"0306-9877"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is it possible to use Proton Pump Inhibitors in COVID-19 treatment and prophylaxis?","name":"articletitle","label":"Article Title"},{"value":"Medical Hypotheses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mehy.2020.110018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110018"}}